Obiettivo Problem Approx. 50% of all patients with severe blood stream infections die from the infections, while the remaining 50% incur excessive socio-economic expenses from prolonged hospital stays. In fact, the fourth largest cause of death in the western world is hospital and care acquired infections, most often caused by urinary catheters. Present state-of-the-art, measuring the temperature of a patient, indicates if the patient has an infection, but with approx. 2-3 days delay, and with many possibilities for false positives (increasing temperature can mean other things than infection).SolutionThe innovation, the Bacticon Catheter, is a catheter impregnation technology based on a new biosensor/biomarker principle based on biomarkers, bio-nanoparticles and nano-channels in a new hybrid material, allowing for an immediate detection. The system is an add-on to existing catheters and is therefore cost efficient and face a faster route through approval procedures, providing much more precise and real-time monitoring.ProjectThe project has three objectives:1: Technological feasibility study: Verify and adjust an integrated prototype 2: User feasibility study: Verify the product need by conducting a market and user study, a product innovation strategy, partner search, feasibility of concept, benchmarking with other products and a go-to-market strategy. 3: Economical feasibility study: Analyse the economical sustainability of the product Business modelThe innovation is well suited to be commercialised through the sales and marketing channels of a med-tech company, which is already established in the market place, and where the Bacticon Catheter can be integrated in the existing product portfolio of such med-tech company. BioModics is pursuing this option as priority one.MarketThe dominating markets are the American market with a 547 M€ urological catheter revenue and Europe with 615 M€. Increasing growth rates are expected, especially in Asia, Europe and US. Campo scientifico engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensorsmedical and health sciencesclinical medicineurologysocial scienceseconomics and businessbusiness and managementbusiness modelsnatural sciencesphysical sciencesopticslaser physics Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Invito a presentare proposte H2020-SMEInst-2014-2015 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2014 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore BIOMODICS APS Contribution nette de l'UE € 50 000,00 Indirizzo STENGARDS ALLE 31 A 2800 Kgs Lyngby Danimarca Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Danmark Hovedstaden Københavns omegn Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00
